Compare HCWB & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCWB | SPHL |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.5M |
| IPO Year | 2021 | 2024 |
| Metric | HCWB | SPHL |
|---|---|---|
| Price | $1.36 | $7.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 56.3K | ★ 5.6M |
| Earning Date | 11-14-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $422,026.00 | ★ $5,956,226.00 |
| Revenue This Year | $178.64 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.95 | $1.92 |
| 52 Week High | $41.20 | $62.40 |
| Indicator | HCWB | SPHL |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 57.94 |
| Support Level | $1.10 | $2.02 |
| Resistance Level | $1.35 | $25.11 |
| Average True Range (ATR) | 0.13 | 2.15 |
| MACD | 0.06 | 0.87 |
| Stochastic Oscillator | 89.07 | 24.47 |
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.